AiCuris’ novel resistance breaking HIV compound AIC292 in phase I
Advertisement
AiCuris announced that its resistance-breaking NNRTI (Non-Nucleosidic Reverse Transcriptase Inhibitor) for HIV has entered human phase I clinical trials.
Following oral administration the compound was generally well tolerated and the resulting pharmacokinetic profile was indicative of the potential for a once daily dosing regime. Commenting on the results Prof. Dr. Helga Rübsamen-Schaeff, CEO of AiCuris, stated ‘’We are very pleased about these results. Due to the chronic course of an HIV infection once daily dosing is one of the key prerequisites for a modern HIV drug in addition to good efficacy and tolerability.”
Like other compounds from AiCuris, AIC292 has a resistance-breaking profile. Prof. Rübsamen-Schaeff: “With this compound we have demonstrated once again the ability to generate innovative and attractive candidates for clinical development with our in house research in collaboration with external partners.”